{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-22-000107","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.238210+00:00","generated_at":"2026-06-22T19:06:02.898762+00:00","sec_items":["2.02","5.03","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nautilus Biotechnology Q3 2022 net loss $14.1M, cash $323.6M; bylaws amended","bullets":["Operating expenses $15.8M for Q3 2022, up 9% YoY from $14.6M.","Net loss $14.1M vs $14.5M in Q3 2021; no revenue (pre-revenue biotech).","Cash, cash equivalents and investments $323.6M as of Sept 30, 2022.","Company advanced platform development including commercial instrument readiness.","Bylaws amended to update stockholder nomination procedures and conform to DGLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-22-000107","json":"https://secwatch.observer/filing/0001808805-22-000107.json","markdown":"https://secwatch.observer/filing/0001808805-22-000107.md","text":"https://secwatch.observer/filing/0001808805-22-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/0001808805-22-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/naut-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T19:06:02.898762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24d9a0a2ad6e7cff20e343e6051dc8ed490fb6e3","claim":"Nautilus Biotechnology, Inc. reported third quarter ended September 30, 2022 results: net income $14.1 million.","evidence_excerpt":"Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/0001808805-22-000107-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$14.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ce118ce8bc5e64975e15efd6ef679f88e9bccfa9","claim":"Nautilus Biotechnology, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting provisions, remove lock-up provisions, update board and officer provisions, and make conforming ministerial changes (effective 2022-10-27).","evidence_excerpt":"On October 27, 2022, the Company’s board of directors, upon recommendation of the nominating and governance committee, amended and restated the Company’s amended and restated bylaws, effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/0001808805-22-000107-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-10-27"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}